Hepatopulmonary Syndrome clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18-99
The purpose of this study is to assess the safety, tolerability and possible benefit of letrozole compared to placebo in patients with Hepatopulmonary Syndrome.
San Francisco, California and other locations
Our lead scientists for Hepatopulmonary Syndrome research studies include Yvonne Kelly, MD.